SCA
RXRX icon

Snowden Capital Advisors’s Recursion Pharmaceuticals RXRX Stock Holding History

Snowden Capital Advisors’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-14,165
Closed -$93.3K – 1256
2024
Q3 		$93.3K Buy
+14,165
New +$102K ﹤0.01% 1197

Other funds holding RXRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
MIC
Mubadala Investment Company Abu Dhabi, United Arab Emirates $20.5B AUM 19.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
KA
Kinnevik AB Stockholm, Sweden $65.6M AUM 25.95% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Snowden Capital Advisors's RXRX Position: Q4 2024 in Review

Snowden Capital Advisors sold out of Recursion Pharmaceuticals (RXRX) in Q4 2024, closing a stake of 14,165 shares — an estimated $93.3K sold.

Snowden Capital Advisors first reported a position in RXRX in Q3 2024 and held it in 1 quarter. The position peaked at $93.3K in Q3 2024. 316 funds tracked by Wall St. Rank hold RXRX as of Q4 2024.

  • Snowden Capital Advisors reported no remaining Recursion Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Snowden Capital Advisors sold 14,165 Recursion Pharmaceuticals shares in Q4 2024, an estimated $93.3K.
  • Snowden Capital Advisors first reported a position in Recursion Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Snowden Capital Advisors's Recursion Pharmaceuticals position peaked at $93.3K in Q3 2024.
  • 316 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q4 2024.

Based on Snowden Capital Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.